Thus, the identification of alternative ways to impair AR signaling, such as that mediated by the miR-1/-26a-1/-487b signature, could be of crucial relevance for developing complementary therapies based on the inhibition of AR signaling in GBM patients. Here, AR is linked to glioblastoma.